In January 2021, the approval of T-DXd was granted for patients with locally advanced or metastatic HER2-positive gastric cancer who previously received a trastuzumab-based therapy as a result of the DESTINY-Gastric01 trial (NCT03329690) [19]. This evidence concerns the gene ERBB2 and gastric cancer.